PYN Phynova

 

TIDMPYN 
 
RNS Number : 1614P 
Phynova Group PLC 
19 March 2009 
 

+-------------------------------------+-------------------------------------+ 
|                                     |                       19 March 2009 | 
+-------------------------------------+-------------------------------------+ 
 
 
Phynova Group plc 
 
 
("Phynova") 
 
 
Annual General Meeting 2009 
 
 
Phynova Group plc (AIM: PYN, OTCQX: PHNVY), the developer of prescription 
pharmaceuticals derived from plants used in Chinese medicines, held its Annual 
General Meeting at Phynova´s offices in Long Hanborough today.  All resolutions 
put to the shareholders, as set out in the notice of annual general meeting 
dated 20 February 2009, were passed by the necessary majorities. 
- Ends - 
For further information, please contact: 
 
 
+--------------------------------------------+----------------------------+ 
| Phynova Group PLC                          | +44 (0) 1993 880700        | 
+--------------------------------------------+----------------------------+ 
| John Pool (Executive Chairman)             |                            | 
+--------------------------------------------+----------------------------+ 
| Tony Mills (CEO Phynova Limited)           |                            | 
+--------------------------------------------+----------------------------+ 
| Robert Miller (CEO Phynova China Limited)  |                            | 
+--------------------------------------------+----------------------------+ 
|                                            |                            | 
+--------------------------------------------+----------------------------+ 
| Nominated Adviser:                         |                            | 
+--------------------------------------------+----------------------------+ 
| John East & Partners Limited               | +44 (0) 20 7618 2200       | 
+--------------------------------------------+----------------------------+ 
| Simon Clements                             |                            | 
+--------------------------------------------+----------------------------+ 
|                                            |                            | 
+--------------------------------------------+----------------------------+ 
| Broker:                                    |                            | 
+--------------------------------------------+----------------------------+ 
| Evolution Securities China Limited         | +44 (0) 20 7071 4389       | 
+--------------------------------------------+----------------------------+ 
| Barry Saint                                |                            | 
+--------------------------------------------+----------------------------+ 
 
 
Media enquiries: 
+--------------------------------------------+----------------------------+ 
| Capital MS&L                               | +44 (0) 20 7307 5330       | 
+--------------------------------------------+----------------------------+ 
| Mary Clark/Anna Mitchell                   |                            | 
+--------------------------------------------+----------------------------+ 
|                                            |                            | 
+--------------------------------------------+----------------------------+ 
 
 
Notes to Editors: 
 
 
About Phynova 
Phynova is a UK company developing new prescription pharmaceuticals derived from 
plants used in Chinese medicines. The Company is focused on viral and bacterial 
diseases, metabolic diseases and cancer. Phynova's lead product for hepatitis C 
has now completed a Phase I/II trial in the US. Two further products, for fatty 
liver disease and post-operative ileus, are targeted for entry to the clinic and 
there are a further four products in preclinical development. 
 
 
For further information please visit www.phynova.com. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 RAGJLMATMMIBBPL 
 

Phynova (LSE:PYN)
Historical Stock Chart
From Jan 2025 to Feb 2025

Phynova (LSE:PYN)
Historical Stock Chart
From Feb 2024 to Feb 2025